Results 11 to 20 of about 94,528 (347)
Regional and intratumoral adoptive T-cell therapy
Immuno-Oncology and TechnologyAdoptive T-cell therapies (ACTs) including tumor-infiltrating lymphocytes and engineered T cells (transgenic T-cell receptor and chimeric antigen receptor T cells), have made an important impact in the field of cancer treatment over the past years.
I. Olivera +4 more
doaj +3 more sources
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy [PDF]
Cancer Cell, 2017 Stefani Spranger +3 more
openalex +3 more sources
Adoptive cell therapy simplified [PDF]
Nature Reviews Clinical Oncology, 2013 Rebecca Kirk
openaire +3 more sources
Adoptive Cell Transfer Therapy [PDF]
Seminars in Oncology, 2007 Adoptive cell transfer therapy has developed into a potent and effective treatment for patients with metastatic melanoma. Current application of this therapy relies on the ex vivo generation of highly active, highly avid tumor-reactive lymphocyte cultures from endogenous tumor infiltrating lymphocytes or on the genetic engineering of cells using ...
Mark E, Dudley, Steven A, Rosenberg
openaire +2 more sources
Adoptive Cell Therapy for Sarcoma [PDF]
Immunotherapy, 2015 Current therapy for sarcomas, though effective in treating local disease, is often ineffective for patients with recurrent or metastatic disease. To improve outcomes, novel approaches are needed and cell therapy has the potential to meet this need since it does not rely on the cytotoxic mechanisms of conventional therapies.
Melinda, Mata, Stephen, Gottschalk
openaire +2 more sources
Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
Frontiers in Oncology, 2021 Esophageal cancer is an exceedingly aggressive and malignant cancer that imposes a substantial burden on patients and their families. It is usually treated with surgery, chemotherapy, radiotherapy, and molecular-targeted therapy. Immunotherapy is a novel
Yu-Ge Zhu +5 more
doaj +1 more source
Adoptive Cell Therapies for Glioblastoma [PDF]
Frontiers in Oncology, 2013 Glioblastoma (GBM) is the most common and most aggressive primary brain malignancy and, as it stands, is virtually incurable. With the current standard of care, maximum feasible surgical resection followed by radical radiotherapy and adjuvant temozolomide, survival rates are at a median of 14.6 months from diagnosis in molecularly unselected patients ...
Kevin James Bielamowicz +8 more
openaire +3 more sources
The Cancer Journal, 2010 Building on the principals that the adoptive transfer of T cells can lead to the regression of established tumors in humans, investigators are now further manipulating these cells using genetic engineering. Two decades of human gene transfer experiments have resulted in the translation of laboratory technology into robust clinical applications.
Richard A, Morgan +2 more
openaire +2 more sources
Journal of Medical Case Reports, 2021 Background Blocking the programmed death 1 pathway by immune checkpoint inhibitors induces dramatic antitumor activity in patients with malignant tumors. However, the clinical response to immune checkpoint inhibitors remains limited owing to the patients’
Rishu Takimoto +7 more
doaj +1 more source
Adoptive T cell therapy of cancer [PDF]
Current Opinion in Immunology, 2010 Adoptive transfer of T cells specific for antigens expressed on tumor cells is an attractive strategy for producing targeted and long-lived anti-tumor activity. T cell therapies have shown activity in selected clinical applications but broader application is limited by inadequate persistence of transferred T cells and by tumor-evasion strategies ...
Malcolm K, Brenner, Helen E, Heslop
openaire +2 more sources